3/24
08:00 am
mlys
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
Low
Report
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
3/20
06:35 am
mlys
Is It Time To Reassess Mineralys Therapeutics (MLYS) After The Recent Share Price Pullback? [Yahoo! Finance]
Low
Report
Is It Time To Reassess Mineralys Therapeutics (MLYS) After The Recent Share Price Pullback? [Yahoo! Finance]
3/17
07:12 am
mlys
R1 starts up with $78M, aiming for a better kidney drug [Yahoo! Finance]
Medium
Report
R1 starts up with $78M, aiming for a better kidney drug [Yahoo! Finance]
3/16
04:05 pm
mlys
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
3/15
01:05 am
mlys
Low
Report
3/13
03:08 pm
mlys
Mineralys Therapeutics (MLYS) had its "hold" rating reaffirmed by Jefferies Financial Group Inc..
Low
Report
Mineralys Therapeutics (MLYS) had its "hold" rating reaffirmed by Jefferies Financial Group Inc..
3/13
03:04 pm
mlys
Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension [Yahoo! Finance]
Low
Report
Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension [Yahoo! Finance]
3/13
12:07 pm
mlys
Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval [Seeking Alpha]
Low
Report
Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval [Seeking Alpha]
3/12
11:14 pm
mlys
Mineralys Therapeutics Inc (MLYS) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Low
Report
Mineralys Therapeutics Inc (MLYS) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
3/12
08:53 pm
mlys
Mineralys Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Mineralys Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
3/12
04:36 pm
mlys
Mineralys Therapeutics GAAP EPS of -$0.40 beats by $0.13 [Seeking Alpha]
Low
Report
Mineralys Therapeutics GAAP EPS of -$0.40 beats by $0.13 [Seeking Alpha]
3/12
04:05 pm
mlys
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
Low
Report
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
3/10
10:09 am
mlys
Mineralys Therapeutics (MLYS) was given a new $56.00 price target by HC Wainwright.
Medium
Report
Mineralys Therapeutics (MLYS) was given a new $56.00 price target by HC Wainwright.
3/9
05:07 pm
mlys
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results [Yahoo! Finance]
Medium
Report
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results [Yahoo! Finance]
3/9
04:30 pm
mlys
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
Medium
Report
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
3/9
08:00 am
mlys
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026
High
Report
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026
3/7
02:59 am
mlys
Medium
Report
3/3
05:54 pm
mlys
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight [Yahoo! Finance]
Low
Report
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight [Yahoo! Finance]
3/3
05:31 pm
mlys
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
Low
Report
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
3/3
05:31 pm
mlys
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
Low
Report
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
2/26
04:22 pm
mlys
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
2/26
04:05 pm
mlys
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2/16
06:27 pm
mlys
Is Mineralys Therapeutics (MLYS) Pricing Reflect The Recent Share Price Pullback [Yahoo! Finance]
Low
Report
Is Mineralys Therapeutics (MLYS) Pricing Reflect The Recent Share Price Pullback [Yahoo! Finance]
2/11
07:00 pm
mlys
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
1/30
12:53 am
mlys
Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones [Yahoo! Finance]
Medium
Report
Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones [Yahoo! Finance]